Weakened live vaccines, e.g. meales/mumps/rubella (MMR) and chickenpox vaccines, are not intentionally given during pregnancy because there is a theoretical risk that a live vaccine could affect the fetus. Although research in the US, Germany and the UK found no injury to the unborn child when the MMR vaccine was inadvertently given just before or during pregnancy women are advised to delay becoming pregnant for one month after having a live vaccine.
There is no need to delay pregnancy after receiving non-live/inactive vaccines, e.g. influenza, tetanus/diphtheria/pertussis, hepatitis B, human papillomavirus (HPV) vaccines.
Menactra® is a meningococcal A,C,Y,W-135 conjugate vaccine used to protect against four groups of Neisseria meningitidis, group A, group C, group Y and group W-135.
Menactra® is used as an alternative vaccine to the meningococcal C conjugate vaccines (Meningitec® and Neisvac-C™) and the meningococcal A,C,Y,W-135 polysaccharide vaccines (Menomune® ACYW-135 and Mencevax® ACYW).
The conjugate and polysaccharide vaccines work differently to generate protection against the bacteria. Protection from the conjugate vaccines lasts longer than that from the polysaccharide vaccines. The conjugate vaccines also generate long term memory cells allowing rapid boosting of immunity years later.
Mencevax® ACWY is used for vaccination of children two years of age and over and adults to protect against four groups of Neisseria meningitidis, group A, group C, group Y and group W-135. Mencevax® is only used in children after the age of two years.
NeisVac-C™ is a menincococcal C conjugate vaccine used to protect against Neisseria meningitidis group C only.
The conjugate and polysaccharide vaccines work differently to generate protection against the bacteria. Protection from the conjugate vaccines lasts longer than that from the polysaccharide vaccines. The conjugate vaccines also generate long term memory cells allowing rapid boosting of immunity years later.
Meningitec® is a menincococcal C conjugate vaccine used to protect against Neisseria meningitidis group C only.
The conjugate and polysaccharide vaccines work differently to generate protection against the bacteria. Protection from the conjugate vaccines lasts longer than that from the polysaccharide vaccines. The conjugate vaccines also generate long term memory cells allowing rapid boosting of immunity years later.
Pneumovax® 23 is used for vaccination of children 2 years of age and over and adults to protect against disease caused by 23 types of Streptococcus pneumonia. Pneumovax® 23 is only used in children after the age of 2 years.
Menomune® is used for vaccination of children two years of age and over and adults to protect against four groups of Neisseria meningitidis, group A, group C, group Y and group W-135. Menomune® is only used in children after the age of two years.
Synflorix® is used for primary and booster vaccination of infants and children up to their 5th birthday to protect against disease caused by 10 types of streptococcus pneumoniae.
Prevenar 13® is used for primary and booster immunisation of infants and children and primary immunisation of adults at increased risk of pneumococcal disease to protect against disease caused by 13 types of Streptococcus pneumoniae.
The vaccine is licensed for use in infants and children up to their 5th birthday and for adults from 50 years of age. It is used out of licensure in children 5-16 years of age and adolescents/adults between 16-49 years of age as there is no alternative pneumococcal conjugate vaccine available in New Zealand for this age group. When the vaccine is administered to individuals between 5-49 years of age, use will be outside of current licensure. There are not expected to be any safety concerns for use in this age group.
IPOL is used for primary and booster vaccination of infants, children and adults to protect against infection with Type 1, Type 2 and Type 3 polioviruses causing poliomyelitis.
